1. Home
  2. CLLS vs PROF Comparison

CLLS vs PROF Comparison

Compare CLLS & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cellectis S.A.

CLLS

Cellectis S.A.

HOLD

Current Price

$4.40

Market Cap

299.0M

Sector

Health Care

ML Signal

HOLD

Logo Profound Medical Corp.

PROF

Profound Medical Corp.

HOLD

Current Price

$7.48

Market Cap

230.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLLS
PROF
Founded
1999
N/A
Country
France
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
299.0M
230.4M
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
CLLS
PROF
Price
$4.40
$7.48
Analyst Decision
Buy
Strong Buy
Analyst Count
1
1
Target Price
$8.00
$11.00
AVG Volume (30 Days)
133.9K
142.9K
Earning Date
11-07-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$82,551,000.00
$14,297,000.00
Revenue This Year
$32.58
$64.23
Revenue Next Year
N/A
$113.06
P/E Ratio
N/A
N/A
Revenue Growth
129.04
67.94
52 Week Low
$1.10
$3.76
52 Week High
$5.48
$7.99

Technical Indicators

Market Signals
Indicator
CLLS
PROF
Relative Strength Index (RSI) 49.34 63.62
Support Level $4.47 $7.19
Resistance Level $5.45 $7.95
Average True Range (ATR) 0.30 0.41
MACD -0.12 0.06
Stochastic Oscillator 31.17 81.72

Price Performance

Historical Comparison
CLLS
PROF

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

About PROF Profound Medical Corp.

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.

Share on Social Networks: